- Home
- FSEA vs CTSO Comparison
FSEA vs CTSO Comparison
Compare FSEA & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- CTSO
- Stock Information
- Founded
- FSEA 1890
- CTSO 1997
- Country
- FSEA United States
- CTSO United States
- Employees
- FSEA N/A
- CTSO N/A
- Industry
- FSEA Savings Institutions
- CTSO Medical/Dental Instruments
- Sector
- FSEA Finance
- CTSO Health Care
- Exchange
- FSEA Nasdaq
- CTSO Nasdaq
- Market Cap
- FSEA 53.7M
- CTSO 57.6M
- IPO Year
- FSEA N/A
- CTSO N/A
- Fundamental
- Price
- FSEA $11.21
- CTSO $1.16
- Analyst Decision
- FSEA
- CTSO Buy
- Analyst Count
- FSEA 0
- CTSO 2
- Target Price
- FSEA N/A
- CTSO $5.50
- AVG Volume (30 Days)
- FSEA 4.5K
- CTSO 324.9K
- Earning Date
- FSEA 08-08-2025
- CTSO 08-07-2025
- Dividend Yield
- FSEA N/A
- CTSO N/A
- EPS Growth
- FSEA N/A
- CTSO N/A
- EPS
- FSEA N/A
- CTSO N/A
- Revenue
- FSEA $14,095,000.00
- CTSO $36,107,520.00
- Revenue This Year
- FSEA N/A
- CTSO $11.15
- Revenue Next Year
- FSEA N/A
- CTSO $21.39
- P/E Ratio
- FSEA N/A
- CTSO N/A
- Revenue Growth
- FSEA 30.26
- CTSO 20.18
- 52 Week Low
- FSEA $8.90
- CTSO $0.71
- 52 Week High
- FSEA $11.80
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- FSEA 43.66
- CTSO 60.19
- Support Level
- FSEA $10.13
- CTSO $1.03
- Resistance Level
- FSEA $11.48
- CTSO $1.22
- Average True Range (ATR)
- FSEA 0.18
- CTSO 0.09
- MACD
- FSEA -0.03
- CTSO 0.03
- Stochastic Oscillator
- FSEA 69.53
- CTSO 86.61
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.